Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Ethics Committee (IRB/EC)~2. Is between the ages of 18 and 75 years old, inclusive~3. Has histologically or cytologically confirmed stage IIIB (malignant pericardial or pleural effusion) or stage IV non-small cell lung cancer~4. Has measurable disease, defined as at least one tumor that fulfills the criteria for a target lesion according to RECIST~5. Has an ECOG performance status of 0 or 1~6. Has a life expectancy of \> 3 months~7. Has adequate hematologic function as evidenced by:~   * ANC ≥ 1,500/μL~  * PLT ≥ 100,000/μL~  * HGB ≥ 9 g/dL obtained within 1 week prior to the first dose of study medication;~8. Has adequate renal function as evidenced by:~   * Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) for the reference lab~  * Urine dipstick for proteinuria of \< 1+ (i.e., either 0 or trace) within 2 weeks of Day 1 If urine dipstick is ≥ 1+, then urine protein excretion must be ≤ 500 mg over a 24 hour collection obtained within 1 week prior to the first dose of study medication;~9. Has adequate hepatic function as evidenced by:~   * Serum total bilirubin ≤ 1.0 mg/dL~  * AST ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases)~  * ALT ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases) obtained within 1 week prior to the first dose of study medication;~10. If a woman of childbearing potential or a fertile man (and his partners), must agree to use an effective form of contraception (hormonal contraceptive, double-barrier method or abstinence) during the study.~Exclusion Criteria:~1. Has received prior systemic chemotherapy at any time for lung cancer;~2. Has received previous radiation therapy to \>30% of active bone marrow or any radiation therapy within 3 weeks of Day 1~3. Has a known hypersensitivity to baker's yeast, or has an active yeast infection~4. Has had previous exposure to Betafectin® or Imprime PGG~5. Has an active infection~6. Presents with any of the following medical diagnoses/conditions at the time of screening:~   * Central nervous system (CNS) metastases~  * Uncontrolled hypertension (\>150/100 mmHg) or hypertension that requires \> two agents for adequate control~  * Peripheral neuropathy ≥ grade 2 from any cause~  * Fever of \>38.5° C within 3 days prior to screening or Day 1, initial dosing~  * Known HIV/AIDs, Hepatitis B, Hepatitis C, connective tissue or autoimmune disease, or other clinical diagnosis, ongoing or intercurrent illness that in the physician's opinion could interfere with participation~7. Has a history of any of the following medical diagnoses/conditions:~   * Myocardial infarction or an unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure) within the previous 6 months~  * Second malignancy within the previous 5 years, other than basal cell carcinoma, cervical intra-epithelial neoplasia or curatively treated prostate cancer with a PSA of \<2.0 ng/mL~8. Has a known hypersensitivity to cetuximab, murine proteins, or any component of cetuximab~9. Has a know sensitivity to Cremophor EL~10. Has previously received treatment with cetuximab~11. If female, is pregnant or breast-feeding~12. Is receiving concurrent investigational therapy or has received investigational therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication)~13. Has previously received an organ or progenitor/stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Imprime PGG (Type: EXPERIMENTAL): Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
- Control (Type: ACTIVE_COMPARATOR): Cetuximab + Paclitaxel/Carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete